{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:16:17Z","timestamp":1783638977187,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Voriconazole (VRCZ) is an effective treatment for pulmonary aspergillosis. Active infectious disease leads to a reduction in cytochrome P450 activity, resulting in increased VRCZ concentrations. However, the impact of VRCZ dose reduction during the severe inflammatory state on VRCZ concentrations after the resolution of inflammation is not yet fully understood. Here, we report the time-course changes in VRCZ blood concentrations after inflammation in a patient with invasive pulmonary aspergillosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A man in his 60s receiving oral VRCZ tablets at 400\u00a0mg\/day for invasive pulmonary aspergillosis developed marked inflammation due to bacterial pneumonia and influenza virus infection. C-reactive protein (CRP) levels increased to a peak of 35.54\u00a0mg\/dL, with a concomitant elevation in the VRCZ trough concentration to 4.7\u00a0\u00b5g\/mL. Following dose reduction to VRCZ 300\u00a0mg\/day, the trough concentration decreased to 1.1\u00a0\u00b5g\/mL on day 11 after dose reduction, while CRP declined to 4.78\u00a0mg\/dL after antibiotic therapy. VRCZ was continued at the same dose. However, four weeks after CRP levels had stabilized, the VRCZ concentration decreased to 0.6\u00a0\u00b5g\/mL. After re-escalation of VRCZ to 400\u00a0mg\/day, the trough concentration returned to the effective therapeutic range of 1.1\u00a0\u00b5g\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After infection is controlled, VRCZ concentrations may decrease to levels below the therapeutic range. Following VRCZ dose reduction during a high inflammatory state, reassessment of trough concentrations after improvement of inflammation may be useful to prevent excessive decreases in VRCZ concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00583-1","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:03:31Z","timestamp":1779120211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed decrease in voriconazole concentration after resolution of inflammation in a patient with invasive pulmonary aspergillosis: a case report"],"prefix":"10.1186","volume":"12","author":[{"given":"Haruka","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Akamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1\u201360. https:\/\/doi.org\/10.1093\/cid\/ciw326.","DOI":"10.1093\/cid\/ciw326"},{"issue":"Suppl 1","key":"583_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002.","journal-title":"Clin Microbiol Infect"},{"key":"583_CR3","doi-asserted-by":"publisher","unstructured":"Lamoth F, Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev. 2022;31. https:\/\/doi.org\/10.1183\/16000617.0114-2022.","DOI":"10.1183\/16000617.0114-2022"},{"key":"583_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","volume":"45","author":"U Theuretzbacher","year":"2006","unstructured":"Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649\u201363. https:\/\/doi.org\/10.2165\/00003088-200645070-00002.","journal-title":"Clin Pharmacokinet"},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","volume":"19","author":"Y Hamada","year":"2013","unstructured":"Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19:381\u201392. https:\/\/doi.org\/10.1007\/s10156-013-0607-8.","journal-title":"J Infect Chemother"},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","volume":"44","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44:183\u201393. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.019.","journal-title":"Int J Antimicrob Agents"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","volume":"58","author":"C Shi","year":"2019","unstructured":"Shi C, Xiao Y, Mao Y, Wu J, Lin N, Voriconazole. A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2019;58:687\u2013703. https:\/\/doi.org\/10.1007\/s40262-019-00735-7.","journal-title":"Clin Pharmacokinet"},{"key":"583_CR8","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1111\/bcp.15495","volume":"88","author":"X Li","year":"2022","unstructured":"Li X, Lai F, Jiang Z, Li M, Chen Z, Cheng J, et al. Effects of inflammation on voriconazole levels: A systematic review. Br J Clin Pharmacol. 2022;88:5166\u201382. https:\/\/doi.org\/10.1111\/bcp.15495.","journal-title":"Br J Clin Pharmacol"},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"107627","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107627.","journal-title":"Pharmacol Ther"},{"key":"583_CR10","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2\u00a0C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35:1687\u201393. https:\/\/doi.org\/10.1124\/dmd.107.015511.","journal-title":"Drug Metab Dispos"},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.1840120517","volume":"12","author":"JV Castell","year":"1990","unstructured":"Castell JV, G\u00f3mez-Lech\u00f3n MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179\u201386. https:\/\/doi.org\/10.1002\/hep.1840120517.","journal-title":"Hepatology"},{"key":"583_CR12","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1128\/aac.03820-14","volume":"58","author":"MJ van Wanrooy","year":"2014","unstructured":"van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58:7098\u2013101. https:\/\/doi.org\/10.1128\/aac.03820-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11095-021-03019-7","volume":"38","author":"F Simon","year":"2021","unstructured":"Simon F, Gautier-Veyret E, Truffot A, Chenel M, Payen L, Stanke-Labesque F, et al. Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates. Pharm Res. 2021;38:415\u201328. https:\/\/doi.org\/10.1007\/s11095-021-03019-7.","journal-title":"Pharm Res"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1248\/bpb.b22-00097","volume":"45","author":"Y Maeda","year":"2022","unstructured":"Maeda Y, Tanaka R, Tatsuta R, Takano K, Hashimoto T, Ogata M, et al. Impact of Inflammation on Intra-individual Variation in Trough Voriconazole Concentration in Patients with Hematological Malignancies. Biol Pharm Bull. 2022;45:1084\u201390. https:\/\/doi.org\/10.1248\/bpb.b22-00097.","journal-title":"Biol Pharm Bull"},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jiac.2023.03.013","volume":"29","author":"K Miyakawa-Tanaka","year":"2023","unstructured":"Miyakawa-Tanaka K, Suzuki J, Hirasawa Y, Nakamura S, Takeda K, Narumoto O, et al. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study. J Infect Chemother. 2023;29:683\u20137. https:\/\/doi.org\/10.1016\/j.jiac.2023.03.013.","journal-title":"J Infect Chemother"},{"key":"583_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.31.5.540","volume":"31","author":"R Hyland","year":"2003","unstructured":"Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540\u20137. https:\/\/doi.org\/10.1124\/dmd.31.5.540.","journal-title":"Drug Metab Dispos"},{"key":"583_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","volume":"72","author":"A Veringa","year":"2017","unstructured":"Veringa A, Ter Avest M, Span LF, van den Heuvel ER, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72:261\u20137. https:\/\/doi.org\/10.1093\/jac\/dkw349.","journal-title":"J Antimicrob Chemother"},{"key":"583_CR18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cpt.2412","volume":"110","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, et al. Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clin Pharmacol Ther. 2021;110:1358\u201367. https:\/\/doi.org\/10.1002\/cpt.2412.","journal-title":"Clin Pharmacol Ther"},{"key":"583_CR19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cpt.2146","volume":"109","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of Acute Inflammation on Cytochromes P450 Activity Assessed by the Geneva Cocktail. Clin Pharmacol Ther. 2021;109:1668\u201376. https:\/\/doi.org\/10.1002\/cpt.2146.","journal-title":"Clin Pharmacol Ther"},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/aac.02830-15","volume":"60","author":"MA Encalada Ventura","year":"2016","unstructured":"Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, et al. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrob Agents Chemother. 2016;60:2727\u201331. https:\/\/doi.org\/10.1128\/aac.02830-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"583_CR21","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/jac\/dkad293","volume":"78","author":"C Boglione-Kerrien","year":"2023","unstructured":"Boglione-Kerrien C, Zerrouki S, Le Bot A, Camus C, Marchand T, Bellissant E, et al. Can we predict the influence of inflammation on voriconazole exposure? An overview. J Antimicrob Chemother. 2023;78:2630\u20136. https:\/\/doi.org\/10.1093\/jac\/dkad293.","journal-title":"J Antimicrob Chemother"},{"key":"583_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1208\/s12248-016-9890-5","volume":"18","author":"X Jiang","year":"2016","unstructured":"Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. Aaps j. 2016;18:767\u201376. https:\/\/doi.org\/10.1208\/s12248-016-9890-5.","journal-title":"Aaps j"},{"key":"583_CR23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/jps.21916","volume":"99","author":"S Schmidt","year":"2010","unstructured":"Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 2010;99:1107\u201322. https:\/\/doi.org\/10.1002\/jps.21916.","journal-title":"J Pharm Sci"},{"key":"583_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115\u201321. https:\/\/doi.org\/10.1067\/mcp.2002.121829.","journal-title":"Clin Pharmacol Ther"},{"key":"583_CR25","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1248\/bpb.b15-00241","volume":"38","author":"T Yamada","year":"2015","unstructured":"Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses. Biol Pharm Bull. 2015;38:1496\u2013503. https:\/\/doi.org\/10.1248\/bpb.b15-00241.","journal-title":"Biol Pharm Bull"},{"key":"583_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fphar.2020.00505","volume":"11","author":"ZQ Yuan","year":"2020","unstructured":"Yuan ZQ, Qiao C, Yang ZC, Yu L, Sun LN, Qian Y, et al. The Impact of Plasma Protein Binding Characteristics and Unbound Concentration of Voriconazole on Its Adverse Drug Reactions. Front Pharmacol. 2020;11:505. https:\/\/doi.org\/10.3389\/fphar.2020.00505.","journal-title":"Front Pharmacol"},{"key":"583_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/bcp.13627","volume":"84","author":"B Vreugdenhil","year":"2018","unstructured":"Vreugdenhil B, van der Velden W, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, et al. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol. 2018;84:1980\u20138. https:\/\/doi.org\/10.1111\/bcp.13627.","journal-title":"Br J Clin Pharmacol"},{"key":"583_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0091270010395510","volume":"52","author":"S Lee","year":"2012","unstructured":"Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012;52:195\u2013203. https:\/\/doi.org\/10.1177\/0091270010395510.","journal-title":"J Clin Pharmacol"},{"key":"583_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","volume":"68","author":"I Scholz","year":"2009","unstructured":"Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906\u201315. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03534.x.","journal-title":"Br J Clin Pharmacol"},{"key":"583_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1248\/bpb.b25-00057","volume":"48","author":"Y Yasui","year":"2025","unstructured":"Yasui Y, Yasui H, Yamamoto Y, Ishizaka T, Hatanaka K, Imoto W, et al. Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients-Impact of High \u03b11-Acid Glycoprotein Levels. Biol Pharm Bull. 2025;48:694\u2013705. https:\/\/doi.org\/10.1248\/bpb.b25-00057.","journal-title":"Biol Pharm Bull"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00583-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:47:26Z","timestamp":1783637246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00583-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00583-1","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not applicable for this case report. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from the patient described in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}